Last reviewed · How we verify
Raltegravir and Abacavir/Lamivudine
Raltegravir and Abacavir/Lamivudine is a Antiretroviral combination (INSTI + NRTI) Small molecule drug developed by Denver Infectious Disease Consultants, PLLC. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy. Also known as: Isentress, Epzicom, RTG, ABC/3TC.
This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (abacavir/lamivudine) at different stages of the viral lifecycle.
This combination inhibits HIV replication by blocking integrase (raltegravir) and reverse transcriptase (abacavir/lamivudine) at different stages of the viral lifecycle. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | Raltegravir and Abacavir/Lamivudine |
|---|---|
| Also known as | Isentress, Epzicom, RTG, ABC/3TC |
| Sponsor | Denver Infectious Disease Consultants, PLLC |
| Drug class | Antiretroviral combination (INSTI + NRTI) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting viral RNA to DNA. Together, they provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Diarrhea
- Nausea
- Headache
- Insomnia
- Hypersensitivity reaction (abacavir)
- Elevated liver enzymes
- Lipodystrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients (PHASE4)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir and Abacavir/Lamivudine CI brief — competitive landscape report
- Raltegravir and Abacavir/Lamivudine updates RSS · CI watch RSS
- Denver Infectious Disease Consultants, PLLC portfolio CI
Frequently asked questions about Raltegravir and Abacavir/Lamivudine
What is Raltegravir and Abacavir/Lamivudine?
How does Raltegravir and Abacavir/Lamivudine work?
What is Raltegravir and Abacavir/Lamivudine used for?
Who makes Raltegravir and Abacavir/Lamivudine?
Is Raltegravir and Abacavir/Lamivudine also known as anything else?
What drug class is Raltegravir and Abacavir/Lamivudine in?
What development phase is Raltegravir and Abacavir/Lamivudine in?
What are the side effects of Raltegravir and Abacavir/Lamivudine?
What does Raltegravir and Abacavir/Lamivudine target?
Related
- Drug class: All Antiretroviral combination (INSTI + NRTI) drugs
- Target: All drugs targeting HIV integrase, HIV reverse transcriptase
- Manufacturer: Denver Infectious Disease Consultants, PLLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in combination antiretroviral therapy
- Also known as: Isentress, Epzicom, RTG, ABC/3TC
- Compare: Raltegravir and Abacavir/Lamivudine vs similar drugs
- Pricing: Raltegravir and Abacavir/Lamivudine cost, discount & access